Following a $1.1 billion take-private agreement, Esperion is presenting new analyses that could expand its bempedoic acid franchise to pediatric patients and refine its use in adults.
Just weeks after agreeing to be acquired by healthcare investment firm Archimed, Esperion Therapeutics Inc. (NASDAQ: ESPR) announced it will present new clinical data for its bempedoic acid products at a major European conference, signaling a continued focus on expanding the drug’s market potential. The presentations, scheduled for the European Atherosclerosis Society (EAS) Congress in late May, will feature new analyses from a pediatric study and the company’s landmark CLEAR Outcomes trial.
“We are pleased to present supportive new data to the global lipid community at EAS Congress 2026, as they highlight the breadth and durability of our bempedoic acid products to meaningfully lower LDL-C levels and reduce the risk of cardiovascular events,” Sheldon Koenig, President and CEO of Esperion, said. He noted the pediatric data supports advancing bempedoic acid into Phase 3 development for children with genetic high-cholesterol conditions.
The new data includes a Phase 2 study showing bempedoic acid lowered LDL-C, or “bad cholesterol,” in children aged six to 17 with heterozygous familial hypercholesterolemia (HeFH) at levels consistent with adults. Another new analysis, presented with partner Daiichi Sankyo Europe, identifies factors associated with achieving a robust 30 percent or greater LDL-C reduction in statin-intolerant adults.
For Archimed, the new data reinforces the value of an asset it agreed to acquire for up to $1.1 billion. The deal provides Esperion shareholders $3.16 per share in cash—a 58 percent premium to the April 30 closing price—plus a contingent value right of up to $100 million tied to future sales milestones for bempedoic acid and another recently acquired drug, Enbumyst.
Expanding the Bempedoic Acid Franchise
The upcoming presentations at the EAS Congress are pivotal for demonstrating the expanding utility of bempedoic acid, marketed as Nexletol and Nexlizet. Success in the pediatric Phase 2 trial is a critical step toward opening a new, lifelong patient population with high unmet needs. Familial hypercholesterolemia is a genetic condition causing dangerously high cholesterol levels from a young age, making early and effective treatment essential.
The encore presentations from the 14,000-patient CLEAR Outcomes trial further build the case for the drug's role in cardiovascular risk reduction, particularly for patients who cannot tolerate statins. These analyses explore the drug's effect on stroke incidence and venous thromboembolism, adding layers of evidence beyond its primary endpoint of lowering MACE (major adverse cardiovascular events). This positions it as a key alternative and add-on therapy in a market dominated by statins and challenged by injectable competitors like Amgen's Repatha.
The Archimed Acquisition
The take-private deal, expected to close in the third quarter of 2026, will provide Esperion with operational and financial flexibility outside the glare of public markets. The transaction's structure highlights where Archimed sees future value. The first milestone payment of $40 million is tied to U.S. net sales of bempedoic acid therapies reaching certain thresholds in 2027.
A second, larger $60 million milestone is contingent on sales of Enbumyst, a novel nasal spray for edema that Esperion acquired with its purchase of Corstasis Therapeutics in March. This indicates the buyout is a dual bet on both the expansion of the existing cholesterol franchise and the successful commercialization of a new cardiovascular asset. Shares of Esperion surged nearly 44 percent in the month following the acquisition announcement, though they remain down 15.7 percent year-to-date.
This article is for informational purposes only and does not constitute investment advice.
